Stifel Maintains Hold on Ionis Pharmaceuticals, Raises Price Target to $50
Portfolio Pulse from Benzinga Newsdesk
Stifel analyst Paul Matteis has maintained a Hold rating on Ionis Pharmaceuticals (NASDAQ:IONS) and increased the price target from $45 to $50.
December 18, 2023 | 3:36 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Stifel analyst Paul Matteis has reaffirmed a Hold rating on Ionis Pharmaceuticals while raising the price target from $45 to $50.
The increase in price target by Stifel suggests a positive outlook on the stock's value, but the Hold rating indicates that the analyst does not see significant short-term price movement. Investors may view the raised target as a sign of potential value, but the Hold rating could temper immediate reactions.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100